Who are Usual Cefepime Infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocephin, Zavicefta, Ceftazidime-Avibactam, CREXONT ER, ceftriaxone 1gm for intravenous infusion, Prolonged Cefepime Infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/usual-cefepime-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Usual Cefepime Infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Usual Cefepime Infusion (Usual Cefepime Infusion) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin antibiotic. Area: Infectious diseases.

phase 3 Cephalosporin antibiotic Penicillin-binding proteins (PBPs) Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Usual Cefepime Infusion (Usual Cefepime Infusion) — Hospital de Clinicas de Porto Alegre. Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Usual Cefepime Infusion TARGET	Usual Cefepime Infusion	Hospital de Clinicas de Porto Alegre	phase 3	Cephalosporin antibiotic	Penicillin-binding proteins (PBPs)
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zavicefta, Ceftazidime-Avibactam	zavicefta-ceftazidime-avibactam	Pfizer	marketed	Cephalosporin antibiotic and beta-lactamase inhibitor combination	Bacterial cell wall synthesis
CREXONT ER	CREXONT ER	Impax Laboratories, LLC	marketed	First-generation cephalosporin antibiotic	Penicillin-binding proteins (PBPs)
ceftriaxone 1gm for intravenous infusion	ceftriaxone 1gm for intravenous infusion	Ain Shams Maternity Hospital	phase 3	Cephalosporin antibiotic	Penicillin-binding protein 1B
Prolonged Cefepime Infusion	Prolonged Cefepime Infusion	Hospital de Clinicas de Porto Alegre	phase 3	Cephalosporin antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin antibiotic class)

Hospital de Clinicas de Porto Alegre · 2 drugs in this class
Ain Shams Maternity Hospital · 1 drug in this class
Arrevus Inc. · 1 drug in this class
Jiangsu Famous Medical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Usual Cefepime Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/usual-cefepime-infusion. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing